Accord BioPharma Expands Its U.S. Biosimilar Portfolio with UDENYCA Acquisition Accord BioPharma has finalized its acquisition of UDENYCA, enhancing its biosimilar offerings. This move signifies a strong commitment to patient care and industry growth.

Accord BioPharma Expands Its U.S. Biosimilar Portfolio with UDENYCA Acquisition #United_States #Raleigh #Accord_BioPharma #UDENYCA #Coherus_BioSciences